News

Vator Securities advises Ascelia Pharma on SEK 60 million Pre-IPO share issue

17 May 2018

Vator Securities acted as Financial Adviser in connection with the transaction raising SEK 60 million.

Dagens PS Appoints Homan Panahi Entrepreneur of the Week

2 February 2018

“Entrepreneur of the Week” highlights entrepreneurs, innovators and business leaders who shape Swedish commerce.

Vator Securities advises Immunovia in record breaking capital raise

20 October 2016

The capital raise of SEK 218.7 million, which was divided into a private placement share issue of SEK 189.9 million and a rights issue of SEK 28.7 million, broke the record for raising of capital for a diagnostics company on NASDAQ First North Stockholm.

Vator Securities successfully completes advisory mission for Biovica

21 June 2016

Vator Securities, a securities company specializing in financial advisory services for fast-growing companies, today announced the completion of a capital raise in an oversubscribed new share issue of SEK 30 million for Biovica International AB.

Vator Securities successfully completes advisory mission for IRRAS

3 May 2016

Vator Securities today announced the completion of a SEK 91.2 million capital raise for IRRAS AB. IRRAS AB is a commercial medical technology company that develops and sells a groundbreaking pump and catheter system for the treatment of cerebral hemorrhage.

Immunovia’s new share issue subscribed to a value of SEK 305 million

19 November 2015

The rights issue of Immunovia AB (publ) (“Immunovia” or ” the Company”) for the Company’s listing on Nasdaq First North was subscribed to SEK 305 million, which corresponds to a subscription ratio of approximately 500 percent.

Vator Securities successfully completes advisory mission for Vikingaliv

11 June 2015

Vator Securities acted as exclusive financial advisor for Vikingaliv and assisted with obtaining both bank financing and share capital.

Vator Securities successfully completes advisory mission for Immunovia

20 May 2015

Immunovia AB is a Swedish molecular diagnostics company that has developed what can become the world’s first robust test for early diagnosis of pancreatic cancer, which is the fourth deadliest cancer form in the world.